The subject invention provides pharmaceutical compounds useful in the
treatment of Type II diabetes. These compounds are advantageous because
they are readily metabolized by the metabolic drug detoxification
systems. Particularly, thiazolidinedione analogs that have been designed
to include esters within the structure of the compounds are provided.
This invention is also drawn to methods of treating disorders, such as
diabetes, comprising the administration of therapeutically effective
compositions comprising compounds that have been designed to be
metabolized by serum or intracellular hydrolases and esterases.
Pharmaceutical compositions of the ester-containing thiazolidinedione
analogs are also taught.
